Drug Trial Radar · NCT02411955
A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: May 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,077
Actual
Start
Jun 2014
Primary completion
Jan 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the therapeutic equivalence and safety of Tazarotene Cream 0.1% and Tazorac® (tazarotene cream 0.1%).
Conditions
- Acne Vulgaris
Interventions
Tazarotene Cream 0.1%Drug
Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
Tazorac®Drug
Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
PlaceboDrug
Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in inflammatory lesion countsTime frame: Week 12
- Change in non-inflammatory lesion countsTime frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.